Clinical trial

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2018-02-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Lung Cancerunresolved

Advanced Malignanciesunresolved

Carcinomaunresolved

Interventions

BrigatinibDRUG · verified · RxNorm: brigatinib

Sponsors & collaborators

Ariad Pharmaceuticalslead sponsor

Mapped research locations

DetroitMichigan, United States1 La JollaCalifornia, United States1 OrangeCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02784158 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.